- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03562130
Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients (REVE)
A Monocentric Single-arm Study to Characterize the Long-term Safety, Efficacy, and Pharmacodynamic of GLP-2 Analog (Revestive®) in the Management of Short Bowel Syndrome Pediatric Patients on Home-parenteral Nutrition (HPN)
Study Overview
Detailed Description
The short bowel syndrome (SBS) may be defined as a severe malabsorption caused by reduction of intestinal absorptive surface following massive resection of the small intestine. Teduglutide (Revestive®) is an analog of glucagon-like peptide 2 (GLP-2), a naturally occurring hormone that regulates the functional and structural integrity of the cells lining the gastrointestinal tract. The aim of the treatment is to maximize intestinal absorption, minimize the inconvenience of diarrhea, and avoid, reduce or eliminate the need for parenteral support (PS) to achieve the best possible quality of life for the patient. The rationale for the use of Revestive® is based on data obtained, especially in the trial in SBS patients.
Treatment with 0.05 mg/kg/day was safe and well tolerated (no recorded side effects).
Patients remained stable despite substantial reduction in parenteral nutrition (PN) supply as evidenced by stable body weight and height, serum electrolytes, pancreatic enzymes and renal function tests.
Treatment was associated with:
- Reduced PN volume and calories delivered by 25 and 45% respectively with 20% of patients weaned off PN during the study period
- Increased Enteral Nutrition (EN) supply in volume and calories by 40 and 62% respectively
- Increased in plasma citrulline during the treatment period, but decreased after Teduglutide discontinuation The recommended dose of Revestive® in children and adolescents (aged 1 to 17 years) is the same as for adults (0.05 mg/kg body weight once daily).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- Hôpital Necker - Enfants Malades
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Being aged from 2 to 18 years old included ;
- Presenting less than 80 cm of residual small intestine with or without the terminal ileum, ileocecal valve and right colon or having less than 120 cm in case of Short Bowel Syndrome (SBS) caused by Hirschsprung disease;
- Being stable on PN support (inability to significantly reduce PN intake for the last six months before inclusion) ;
- Being dependent on PN for at least 2 years and enterally fed (oral or tube feeding) ;
- Having a normal colonoscopy in the 12 months before screening for children with maintained colon (=SBS type 2 or 3) older than 12 years ;
- Having signed the Informed consent form (or parents or legal representative for minor patients).
Exclusion Criteria:
- Having a major gastrointestinal surgical intervention like serial transverse enteroplasty or any other bowel lengthening procedure performed within 6 months of screening ;
- Having a clinically significant untreated intestinal obstruction or active stenosis ;
- Having an unstable absorption due to cystic fibrosis or known DNA abnormalities ;
- Presenting a radiographic or manometric evidence of pseudo-obstruction or severe known dysmotility syndrome, including persistent, severe gastroschisis-related motility disorders ;
- Having an unstable cardiac disease, congenital heart disease or cyanotic disease, with the exception of patients who had undergone ventricular or atrial septal defect repair ;
- Having a history of cancer or clinically significant lymphoproliferative disease; excepted resected cutaneous basal or squamous cell carcinoma, or in situ non-aggressive and surgically resected cancer ;
- Having participated in a clinical study using an experimental drug within 1 month or an experimental antibody treatment within 3 months prior to screening, or concurrent participation in any clinical study using an experimental drug that would affect the safety of teduglutide ;
- Having already used native GLP-2 and glucagon-like peptide-1 analog or human growth hormone within 3 months prior to screening ;
- Having already used oral or IV glutamine, octreotide, or dipeptidyl peptidase IV (DPP-IV) inhibitors within 3 months prior to screening ;
- Having an active Crohn's disease which has been treated with biological therapy within the 6 months prior to screening ;
- Having an intestinal polyposis;
- Being, for female patient, both lactating and breast-feeding or having a positive pregnancy test during the screening period;
- Refusing the follow the protocol requirements in terms of birth control ;
- Being unable to follow the study procedures for any reason: psychological, geographical…
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of Summary of Product Characteristics (SPC), or trace residues of tetracycline.
- Active or suspected malignancy.
- Patients with a history of malignancies in the gastrointestinal tract including the hepatobiliary system within the last five years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Revestive
Revestive® (teduglutide)is administered in children sub cutaneous injection at 0.05 mg/kg body weight once daily
|
Daily sub cutaneous injection 0,05 mg/kg/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in parenteral nutrition: Parenteral Nutrition/Resting Energy Expenditure (PN/REE)
Time Frame: At week 24
|
Evaluate the efficacy of Revestive® treatment
|
At week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ostomy output defined as stool balance testing, urine output and plasma citrulline
Time Frame: up to week 48
|
Evaluate the impact of Revestive on ostomy flow
|
up to week 48
|
Change in days per week of Parenteral Nutrition (PN)
Time Frame: up to week 48
|
Quantify the impact of Revestive on the number of perfusion in a week
|
up to week 48
|
Change in number of stool per day
Time Frame: up to week 48
|
to evaluate the impact of Revestive on diarrhea
|
up to week 48
|
Change in stools consistency (Bristol stool chart)
Time Frame: up to week 48
|
to evaluate the impact of Revestive on diarrhea
|
up to week 48
|
Ingesta (calorimetric measure)
Time Frame: Every 4 weeks up to week 48
|
to evaluate the impact of Revestive on Intestinal absorption
|
Every 4 weeks up to week 48
|
Stool weight/24h
Time Frame: Every 4 weeks up to week 48
|
to evaluate the impact of Revestive on Intestinal absorption
|
Every 4 weeks up to week 48
|
Percentage of lipid in stool
Time Frame: Every 4 weeks up to week 48
|
to evaluate the impact of Revestive on Intestinal absorption
|
Every 4 weeks up to week 48
|
Percentage of nitrogen in stool
Time Frame: Every 4 weeks up to week 48
|
to evaluate the impact of Revestive on Intestinal absorption
|
Every 4 weeks up to week 48
|
Percentage of carbohydrate in stool
Time Frame: Every 4 weeks up to week 48
|
to evaluate the impact of Revestive on Intestinal absorption
|
Every 4 weeks up to week 48
|
Percentage of sodium in stool
Time Frame: Every 4 weeks up to week 48
|
to evaluate the impact of Revestive on Intestinal absorption
|
Every 4 weeks up to week 48
|
Number of adverse events
Time Frame: At week 48
|
to evaluate the long term safety of Revestive
|
At week 48
|
Change in body weight
Time Frame: At baseline, then at 6 and 12 months
|
At baseline, then at 6 and 12 months
|
|
Change in heart rate
Time Frame: At baseline, then at 6 and 12 months
|
At baseline, then at 6 and 12 months
|
|
Change in blood pressure
Time Frame: At baseline, then at 6 and 12 months
|
At baseline, then at 6 and 12 months
|
|
Endogenous GLP-2 rates (antibody ELISA)
Time Frame: up to week 48
|
to evaluate the response rate of Revestive
|
up to week 48
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P171002J
- 2017-001405-32 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Short Bowel Syndrome
-
Marathon Pharmaceuticals, LLCWithdrawnShort Bowel Syndrome | Short Gut Syndrome | SBS | Short Gut | Short BowelUnited States
-
Central Hospital, Nancy, FranceBeaujon Hospital; Société Francophone Nutrition Clinique et MétabolismeUnknownSBS - Short Bowel SyndromeFrance
-
TakedaRecruitingShort Bowel Syndrome (SBS)Canada
-
GlyPharma TherapeuticsVectivBio AGCompletedSBS - Short Bowel SyndromeDenmark
-
TakedaCompletedShort Bowel Syndrome (SBS)Brazil
-
ShireRecruitingShort Bowel Syndrome (SBS)United States
-
Marathon Pharmaceuticals, LLCWithdrawnShort Bowel Syndrome | Short Gut Syndrome | SBS | Short GutUnited States
-
University of Texas Southwestern Medical CenterChildren's Hospital of PhiladelphiaEnrolling by invitationShort Gut SyndromeUnited States
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaRecruiting
-
University of MiamiQOL Medical, LLCRecruitingShort Gut SyndromeUnited States
Clinical Trials on Teduglutide
-
ShireCompletedCrohn's DiseaseUnited States, Canada
-
ShireCompletedCrohn's DiseaseUnited States, Canada
-
ShireCompletedShort Bowel SyndromeUnited States, Denmark, France, Canada, Belgium, Netherlands, Poland, United Kingdom
-
ShireCompletedShort Bowel SyndromeUnited States, France, Germany, Canada, Netherlands, Poland, Denmark, Belgium, United Kingdom
-
ShireCompletedShort Bowel SyndromeUnited States, United Kingdom
-
ShireCompletedShort Bowel SyndromeUnited States, Canada, Finland, Belgium, Italy, United Kingdom, Germany
-
ShireNycomed Germany GmbHCompletedShort Bowel SyndromeSpain, United States, Canada, France, Denmark, Poland, Germany, Italy, United Kingdom
-
ShireCompleted
-
University Health Network, TorontoCompleted
-
ShireCompletedPharmacokinetics and Safety of Elevated DosesUnited States